Trial Information
A Phase II Study of Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer
Inclusion Criteria:
- Confirmed histopathologic diagnosis of nasopharyngeal squamous cell carcinoma
requiring primary radiation
- less than 70 yrs of age
- Stage T1-T4; N0-N3; M0
- KPS less than 70
- no prior RT to H&N or chemotherapy for H&N
- no other malignancy except non-melanomatous skin cancer
- no distant mets
- no contraindication to RT or chemotherapy
- adequate organ function
- informed consent
Exclusion Criteria
- Major medical or psychiatric illness, which would interfere with either completion of
therapy and follow-up or with full and complete understanding of the risks and
potential complications of the therapy.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
The primary objective of this study is to evaluate 3 year local progression free survival in patients with nasopharyngeal carcinoma treated with Intensity Modulated Radiation Therapy (IMRT) techniques.
Principal Investigator
Andrew Bayley, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Princess Margaret Hospital, Canada
Authority:
Canada: Ethics Review Committee
Study ID:
UHN REB 03-0158-C
NCT ID:
NCT00188877
Start Date:
June 2003
Completion Date:
Related Keywords:
- Nasopharyngeal Neoplasms
- Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Neoplasms